Anthony Quinn

Anthony Quinn is Founder at IDBioPharm Consulting LLC.

Content by Anthony Quinn:

 Tools & Techniques Drug delivery

A Rare Delight

| Anthony Quinn

Anthony Quinn shares the story behind the development and approval of sebelipase alfa (Kanuma) – the first and only enzyme replacement therapy for lysosomal acid lipase deficiency (LAL-D).
Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register

October Issue of The Translational Scientist